Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of NYX-458 in Healthy Volunteers

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study of NYX-458 in Healthy Volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2018

At a glance

  • Drugs NYX-458 (Primary)
  • Indications Cognition disorders
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors Aptinyx
  • Most Recent Events

    • 14 Aug 2018 According to an Aptinyx media release, trial completion expected in first half of 2019.
    • 08 Aug 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top